Rosanna Santoro

San Giovanni Rotondo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Progress in promising anti-fibrotic therapies.

Progress in promising anti-fibrotic therapies.

Journal: Expert review of gastroenterology & hepatology
Published: November 07, 2019

Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

Journal: PloS one
Published: September 26, 2019

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.

Journal: Cells
Published: March 07, 2019

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

Journal: PloS one
Published: March 03, 2019

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Journal: Gastroenterology
Published: August 22, 2018

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.

Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 08, 2018

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Journal: Scientific reports
Published: May 25, 2018

Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.

Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.

Journal: PloS one
Published: May 11, 2018

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

Journal: Alimentary pharmacology & therapeutics
Published: January 16, 2018

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Journal: Gastroenterology
Published: September 13, 2017

Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.

Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.

Journal: Alimentary pharmacology & therapeutics
Published: August 15, 2017

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Journal: Alimentary pharmacology & therapeutics
Published: March 18, 2017
Showing 1-12 of 20

Last Updated: 09/26/2026